Trial Profile
A Phase I C Clinical Study With Influenza Antiviral DAS181-F03: Double-Blind, Randomized, Placebo-Controlled, Single Dose and Multiple Dose Escalation Study in Healthy Adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Oplunofusp (Primary)
- Indications Influenza A virus H1N1 subtype; Influenza virus infections
- Focus Adverse reactions
- 22 Mar 2012 Planned End Date changed from 1 Oct 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 19 May 2011 Planned End Date changed from 1 Mar 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 07 Oct 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.